Will the DSM-5 changes in criteria for premenstrual dysphoric disorder impact clinical practice?

Cirillo, Patricia; Passos, Roberta Benitez Freitas; López, José Ramón Rodriguez Arras; Nardi, Antônio Egídio

doi:10.1590/1516-4446-2013-1332

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the inclusion of PMDD in the DSM-5, some changes have been implemented [ 8 ]: "distress" in addition to interference, a more precise timing of the onset and the offset of the premenstrual symptoms, possibility of co-occurrence of other mental disorders, possibility of a provisional diagnosis based on clinical history, and distinctiveness from substance use or another medical condition. In particular, the possibility of a provisional diagnosis is an important change as it allows an earlier diagnosis and thus earlier access to healthcare for suffering women [ 9 ]. Also the extension of the interference criteria with the expression of distress is essential as it takes into account that women may maintain their function with a high level of distress without suffering from interference in functioning [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Internet-based cognitive behavioural self-help for premenstrual syndrome: study protocol for a randomised controlled trial

Kues

Janda

Kleinstäuber

et al. 2014

Trials

View full text Add to dashboard Cite

BackgroundWith a prevalence of 3 to 8% among women of reproductive age, severe premenstrual symptoms are very common. Symptoms range from emotional and cognitive to physical changes. Severe symptoms (that is, premenstrual syndrome) can have a strong impact on everyday functioning and quality of life. Impairment can be as serious as that of dysthymic disorders. Many affected women receive either no treatment at all or are unsatisfied with their treatment. Although there is some evidence for the reduction of distress through cognitive behavioural therapy, there are only a small number of randomised controlled trials carefully investigating the efficacy of this psychotherapeutic approach. Thus, this study aims to evaluate the efficacy of a cognitive behavioural self-help treatment for women suffering from premenstrual syndrome.Methods/designThe study is conducted as a randomised controlled trial. The complex diagnostic assessment includes the completion of a symptom diary over two consecutive cycles and a telephone interview. Eligible women are randomly assigned to either a treatment or a wait-list control group. The intervention is based on cognitive behavioural therapy principles and is provided via the internet. It consists of 14 different modules on which participants work over 8 consecutive weeks. In addition to written information, participants receive email feedback from a clinical psychologist on a weekly basis. Participants assigned to the wait-list receive the treatment after the end of the waiting period (8 weeks). The primary outcome measure is the Premenstrual Syndrome Impairment Measure. Secondary outcomes include the Premenstrual Syndrome Coping Measure, the Short-Form Social Support Questionnaire, the Questionnaire for the Assessment of Relationship Quality, and the Perceived Stress Scale. Data is collected during the premenstrual (luteal) phase at pre-treatment, post-treatment, and 6-month follow-up.DiscussionSo far, there is no study investigating internet-based cognitive behavioural therapy for premenstrual syndrome. The programme approaches the problem of high prevalence in combination with severe impairment and insufficient treatment options.Trial registrationClinicalTrials.gov: NCT01961479, 9 October 2013.

show abstract

Section: Introductionmentioning

confidence: 99%

Internet-based cognitive behavioural self-help for premenstrual syndrome: study protocol for a randomised controlled trial

Kues

Janda

Kleinstäuber

et al. 2014

Trials

View full text Add to dashboard Cite

show abstract

“…At this stage, whether the inclusion of PMDD in the DSM-V depressive disorder chapter as a full criteria condition will encourage research on the topic as expected is still to be seen [221].…”

Section: Magnitude and Burden Of Dysmenorrhea And Pmsmentioning

confidence: 99%

The magnitude, long-term trend and lifestyle risk factors of dysmenorrhea and premenstrual syndrome

Ju¹

View full text Add to dashboard Cite

show abstract

Premenstrual Dysphoric Disorder Without Comorbid Psychiatric Conditions: A Systematic Review of Therapeutic Options

Sepede¹,

Sarchione²,

Matarazzo³

et al. 2016

Clin Neuropharm

View full text Add to dashboard Cite

Based on the results of our qualitative synthesis, the best therapeutic option in the treatment of adult PMDD patients free of other mental disorders are selective serotonin reuptake inhibitor antidepressants (especially paroxetine and fluoxetine) and low doses of oral estroprogestins. Other interventions, such as light therapy, cognitive behavioral therapy, food supplements, and herbal medicines, showed promising effects, but other investigations are needed to confirm their efficacy.

show abstract

Will the DSM-5 changes in criteria for premenstrual dysphoric disorder impact clinical practice?

Cited by 3 publications

References 4 publications

Internet-based cognitive behavioural self-help for premenstrual syndrome: study protocol for a randomised controlled trial

Internet-based cognitive behavioural self-help for premenstrual syndrome: study protocol for a randomised controlled trial

The magnitude, long-term trend and lifestyle risk factors of dysmenorrhea and premenstrual syndrome

Premenstrual Dysphoric Disorder Without Comorbid Psychiatric Conditions: A Systematic Review of Therapeutic Options

Contact Info

Product

Resources

About